Key points are not available for this paper at this time.
The addition of bevacizumab to combination chemotherapy in patients with recurrent, persistent, or metastatic cervical cancer was associated with an improvement of 3.7 months in median overall survival. (Funded by the National Cancer Institute; GOG 240 ClinicalTrials.gov number, NCT00803062.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Krishnansu S. Tewari
Michael W. Sill
Harry J. Long
New England Journal of Medicine
Massachusetts General Hospital
Memorial Sloan Kettering Cancer Center
University of Arizona
Building similarity graph...
Analyzing shared references across papers
Loading...
Tewari et al. (Wed,) studied this question.
www.synapsesocial.com/papers/69d768fff44a16d01ef30d86 — DOI: https://doi.org/10.1056/nejmoa1309748
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: